Updated rhinitis guideline (2017) from the British Association of Allergy and Clinical Immunology http://www.bsaci.org/Guidelines/rhinitis-2nd-edition-guideline

• Allergic rhinitis is common and affects 10–15% of children and 26% of adults in the UK
• Affects quality of life, school and work attendance, and is a risk factor for development of asthma.
• Diagnosed by history and examination, supported by specific allergy tests.
• Topical nasal corticosteroids are the treatment of choice for moderate to severe disease
• Combination therapy with intranasal corticosteroid plus intranasal antihistamine is more effective than either alone and provides second line treatment for those with rhinitis poorly controlled on monotherapy
• Immunotherapy is highly effective when the specific allergen is the responsible driver for the symptoms
• Treatment of rhinitis is associated with benefits for asthma
• Non-allergic rhinitis also is a risk factor for the development of asthma
• Non-allergic rhinitis may be a presenting complaint for systemic disorders such as granulomatous / eosinophilic polyangiitis, sarcoidosis